<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Possible prevention and therapy of ischemic acute tubular necrosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Possible prevention and therapy of ischemic acute tubular necrosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Possible prevention and therapy of ischemic acute tubular necrosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tushar A Chopra, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark D Okusa, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 31, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) due to ischemic acute tubular necrosis (ATN) typically lasts 7 to 21 days [<a href="#rid1">1</a>], with most patients returning to or near their previous baseline level of kidney function as the necrotic tubular cells regenerate.</p><p>Possible preventive and therapeutic measures for ischemic ATN will be reviewed here.</p><p>The pathogenesis and prognosis of ATN are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7225.html" rel="external">"Kidney and patient outcomes after acute kidney injury in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7228.html" rel="external">"Pathogenesis and etiology of ischemic acute tubular necrosis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">ACUTE KIDNEY INJURY VERSUS ACUTE TUBULAR NECROSIS</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) is characterized by an acute reduction of glomerular filtration rate (GFR) and defined by a rise in the serum creatinine concentration or a decline in urine output that has developed within hours to days  (<a class="graphic graphic_table graphicRef83168" href="/z/d/graphic/83168.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/7238.html" rel="external">"Definition and staging criteria of acute kidney injury in adults"</a>.)</p><p>AKI is commonly, though not always, caused by ATN, particularly among critically ill hospitalized patients.</p><p>Other causes of AKI are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients", section on 'Major causes and classification of AKI'</a>.)</p><p>ATN is caused by ischemia, nephrotoxins, and sepsis and is often multifactorial. In patients with septic shock, it is often not clear whether ATN is caused by ischemia or sepsis.</p><p class="headingAnchor" id="H3497970391"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of ischemic ATN is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7228.html" rel="external">"Pathogenesis and etiology of ischemic acute tubular necrosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The first step in preventing ischemic ATN is to identify the patient at increased risk. In patients at risk for or who may have early ischemic ATN, we optimize volume status with intravenous (IV) fluids (if necessary), with the goal of optimizing cardiac preload, cardiac output, and ultimately renal blood flow.</p><p>Additional measures include the avoidance of nephrotoxins and hypotension, which is a surrogate for reduced renal blood flow. Vasopressors and/or inotropes may be used in clinically significant hypotension refractory to volume optimization. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p class="headingAnchor" id="H1059672024"><span class="h2">Identification of high-risk patients</span><span class="headingEndMark"> — </span>We consider patients to be at high risk of ischemic ATN if they have predisposing comorbidities and have conditions or are undergoing procedures associated with ATN. These comorbidities, conditions, and procedures are listed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Predisposing comorbidities </strong>– Patients with any of the following comorbidities are predisposed to ischemic ATN [<a href="#rid2">2-9</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic kidney disease (CKD; either reduced estimated glomerular filtration rate [eGFR] or proteinuria with normal eGFR)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe atherosclerosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diabetes mellitus, even in the absence of microalbuminuria or reduced eGFR</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Advanced malignancy, obesity, and/or poor nutrition</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditions and procedures associated with ATN</strong> – Conditions and procedures that are associated with ATN include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sepsis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Marked hypovolemia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe pancreatitis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiogenic shock</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemorrhagic shock</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Major surgery (particularly cardiac surgery, abdominal aortic aneurysm surgery, surgery to correct obstructive jaundice, emergent surgery, or surgical re-exploration)</p><p></p><p class="bulletIndent1">All patients with at least one of the comorbidities listed above who have conditions or are undergoing procedures associated with ATN should have interventions designed to reduce ATN risk. (See <a class="local">'Interventions to decrease risk'</a> below.)</p><p></p><p class="bulletIndent1">Various strategies have been devised to improve the identification of high-risk patients. Automated alerts and risk scores, discussed below, are evolving but have had limited success.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Automated alerts</strong> – Because implementation of strategies to prevent the development and/or worsening of acute kidney injury (AKI) is often hampered by clinician-related delays in diagnosis, automated alerts have emerged as a potential modality to alter clinician behavior. Alerts have not been shown to improve survival or reduce the need for kidney replacement therapy (KRT) [<a href="#rid10">10-13</a>]. However, many alert systems have broadly targeted all patients; it is possible that alerts focused on selected subpopulations may have benefit [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk scores</strong> – Various risk scores have been used to predict AKI in different high-risk settings, such as cardiac surgery. However, these risk scores need to be validated in larger populations [<a href="#rid15">15</a>]. Artificial intelligence has been used by some centers to generate AKI risk scores and to provide patient-specific recommendations for managing AKI [<a href="#rid16">16,17</a>]. The impact of machine-based learning on patient outcomes will have to be evaluated in future studies.</p><p></p><p class="headingAnchor" id="H3503759147"><span class="h2">Interventions to decrease risk</span><span class="headingEndMark"> — </span>Patients who are at high risk for ischemic ATN should have interventions to change modifiable risk factors. These interventions include optimizing volume status, avoiding or stopping nephrotoxins, if possible, and dose adjustment for drugs excreted by the kidney. </p><p>We do <strong>not</strong> administer any pharmacologic agent (such as diuretics or <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>/<a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>) for the prevention of ischemic ATN. Although some pharmacologic agents have shown promise in the prevention of ischemic ATN, conflicting results have been reported in different studies or their efficiency is yet to be confirmed. (See <a class="local">'Experimental and unproven measures for the prevention of ischemic ATN'</a> below.)</p><p>Using preventive measures can improve kidney outcomes in high risk settings, such as cardiac surgery [<a href="#rid18">18,19</a>]. In one study for example, implementing the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines strategy, which included avoidance of nephrotoxic agents, discontinuation of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), avoidance of hyperglycemia after surgery, and careful monitoring of serum creatinine, urine output, and volume status, reduced the rate of AKI in high-risk patients after cardiopulmonary bypass surgery (55 versus 72 percent) [<a href="#rid18">18</a>]. </p><p>Our approach to decreasing risk of ischemic ATN is discussed below.</p><p class="headingAnchor" id="H3943080265"><span class="h3">Multidisciplinary approach</span><span class="headingEndMark"> — </span>We endorse a multidisciplinary approach to the prevention and mitigation of AKI in high-risk patients. Collaboration among heterogeneous health care professionals (primary care doctors, emergency department clinicians, pharmacists, advanced practice providers, and nurses) is essential.</p><p>The effectiveness of a multidisciplinary approach is illustrated by quality improvement projects such as The Nephrotoxic Injury Negated by Just-in-Time Action (NINJA) program. In NINJA, rounding pharmacists were alerted if critically ill pediatric patients were exposed to more than three nephrotoxic medications or IV aminoglycoside for three or more days [<a href="#rid20">20</a>]. The use of NINJA was associated with a substantial reduction in the incidence of AKI.</p><p class="headingAnchor" id="H8"><span class="h3">Optimizing volume status and maintaining hemodynamic stability</span><span class="headingEndMark"> — </span>Among all patients at increased risk for ATN, we optimize volume status with IV fluids (if necessary) and maintain adequate hemodynamic status to ensure kidney perfusion. (See  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a>.)</p><p>The exact approach varies based upon patient characteristics and the particular clinical setting.</p><p>The rationale for optimizing volume status relies on numerous well-designed studies that showed that volume expansion prior to exposure to iodinated radiocontrast agents or nephrotoxins lowers the risk of ATN. Details concerning the studies that have examined this issue are available in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">"Prevention of contrast-associated acute kidney injury related to angiography"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity", section on 'Intravenous saline'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity", section on 'Salt loading'</a>.)</p><p></p><p>By comparison, a paucity of data exists concerning the efficacy of volume expansion to lower the risk of ischemic ATN, and many of the studies may reflect interventions that target early secondary prevention (ie, injury has occurred already) rather than true primary prevention. The best data are provided by a meta-analysis of 20 randomized, controlled trials that investigated the renoprotective effects of perioperative hemodynamic optimization among 4220 surgical patients who were undergoing elective or emergent procedures [<a href="#rid21">21</a>].</p><p>Postoperative AKI was reduced by perioperative hemodynamic optimization compared with the control group (odds ratios [OR] 0.64, 95% CI 0.50-0.83). This benefit was seen when optimization was initiated preoperatively, as well as intraoperatively and postoperatively, suggesting that ischemic injury can be prevented or effectively treated with prompt reperfusion.</p><p>Fluid administration should be assessed at regular intervals intraoperatively and postoperatively. (See  <a class="medical medical_review" href="/z/d/html/2296.html" rel="external">"Maintenance and replacement fluid therapy in adults"</a>.)</p><p>Vasopressors and/or inotropes should be reserved for consideration in patients with remarkable hemodynamic instability despite adequate volume repletion. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p>The preferred choice of IV fluids for volume expansion, such as crystalloid (eg, isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">Lactated Ringer</a>'s, or bicarbonate solution) or synthetic colloid (eg, hydroxyl ethyl starch), is unclear and depends on the clinical scenario [<a href="#rid22">22-24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Choice of replacement fluid'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5633.html" rel="external">"Management of acute pancreatitis", section on 'Initial management'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Intravenous fluids (first three hours)'</a>.)</p><p></p><p class="headingAnchor" id="H2404477437"><span class="h3">Avoiding nephrotoxins</span><span class="headingEndMark"> — </span>Obvious nephrotoxins, such as aminoglycosides, amphotericin, radiocontrast agents, and nonsteroidal antiinflammatory agents (NSAIDs), should be avoided, if possible, among patients who are at high risk for ATN. <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> alone [<a href="#rid25">25</a>] or in combination with <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a>/tazobactam [<a href="#rid26">26</a>] may also increase the risk of ATN.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2364.html" rel="external">"Amphotericin B nephrotoxicity"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">"Prevention of contrast-associated acute kidney injury related to angiography"</a>.)</p><p></p><p class="headingAnchor" id="H1346827718"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Because ACE inhibitors, ARBs, and sodium-glucose cotransporter 2 (SGLT2) inhibitors affect renal hemodynamics, the use of these agents has been suggested as a potential risk factor for the development of ATN. </p><p class="headingAnchor" id="H1823771558"><span class="h4">ACE inhibitors and ARBs</span><span class="headingEndMark"> — </span>Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are generally held in patients with low blood pressure, which is a common characteristic of many conditions that predispose to ATN.</p><p>We discontinue ACE inhibitors and ARBs in high-risk patients who have sepsis, marked hypovolemia, severe pancreatitis, cardiogenic shock, or hemorrhagic shock. The ACE inhibitor or ARB may be resumed after the patient clinically improves. (See <a class="local">'Identification of high-risk patients'</a> above.) </p><p>The management of high-risk patients who are taking ACE inhibitors and ARBs preoperatively is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4814.html" rel="external">"Perioperative medication management", section on 'ACE inhibitors and angiotensin II receptor blockers'</a>.)</p><p class="headingAnchor" id="H186722990"><span class="h4">SGLT2 inhibitors</span><span class="headingEndMark"> — </span>Patients taking sodium-glucose cotransporter 2 (SGLT2) inhibitors do not appear to have an increased risk of AKI [<a href="#rid27">27-29</a>]. However, these agents are generally stopped in many high-risk settings (eg, surgery) due to concerns about diabetic ketoacidosis or volume depletion. (See  <a class="medical medical_review" href="/z/d/html/1753.html" rel="external">"Perioperative management of blood glucose in adults with diabetes mellitus", section on 'Oral agent or noninsulin injectable medication'</a>.)</p><p class="headingAnchor" id="H1917977755"><span class="h3">Procedure-related measures</span><span class="headingEndMark"> — </span>As noted, the major surgeries most commonly associated with ATN are cardiac surgery, particularly valve surgery, abdominal aortic aneurysm surgery, and surgery to correct obstructive jaundice. (See <a class="local">'Identification of high-risk patients'</a> above.)</p><p>Among patients undergoing cardiopulmonary bypass surgery, multiple measures to decrease the risk of ATN have been evaluated including cardioplegia, temperature manipulation, use of specific materials to decrease inflammation, pulsatile perfusion via an intra-abdominal balloon pump, and off-pump surgery [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Off-pump cardiopulmonary bypass surgery</strong> – Some [<a href="#rid30">30-32</a>], though not all [<a href="#rid33">33-35</a>], studies have suggested that there is a benefit to off-pump cardiopulmonary bypass surgery in decreasing the risk of mild AKI but not severe, dialysis-requiring AKI, especially among patients with underlying CKD.</p><p></p><p class="bulletIndent1">A 2010 meta-analysis including 22 randomized trials (4819 patients) found that off-pump coronary artery bypass grafting (CABG) was associated with a 40 percent lower odds of postoperative AKI and a nonstatistically significant 33 percent lower odds of dialysis requirement, with no discernible mortality benefit [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1">No difference in effect was seen based on preoperative serum creatinine [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1">The best data subsequent to this meta-analysis are from the CABG Off or On Pump Revascularization Study (CORONARY) trial, which randomly assigned 4752 patients scheduled to undergo isolated CABG surgery to either an off- or on-pump procedure [<a href="#rid38">38</a>]. The use of off-pump CABG did not reduce the risk of the primary composite outcome, which included dialysis-requiring new-onset kidney injury at 30 days, although it did reduce the risk of mild AKI at 30 days. The CORONARY trial is discussed at length elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1558.html" rel="external">"Off-pump and minimally invasive direct coronary artery bypass graft surgery: Clinical use", section on 'Outcomes'</a>.)</p><p></p><p class="bulletIndent1">Subgroup analysis of the CORONARY trial showed that the relative risk (RR) reduction conferred by off-pump surgery was greater among patients with baseline eGFR &lt;60 mL/min/1.73 m<sup>2</sup> CKD (RR 0.63) compared with those with eGFR ≥60 mL/min/1.73 m<sup>2</sup> (RR 0.98) [<a href="#rid39">39</a>]. However, there was no difference between groups in kidney function at one year, even in subgroup analysis of patients with CKD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulsatile perfusion</strong> – Pulsatile perfusion via an intra-abdominal balloon pump using an automatic mode (in which the pump continues to function throughout cardioplegic arrest) may protect kidney function, although studies that have examined this are limited due in part to inaccurate estimates of kidney function.</p><p></p><p class="bulletIndent1">In one study that compared pulsatile perfusion using the automatic mode versus nonpulsatile perfusion among patients with mild to moderate CKD (eGFR &gt;45 mL/min/1.73 m<sup>2</sup>), a higher eGFR was observed with pulsatile perfusion (74 versus 58 mL/min/1.73 m<sup>2</sup>), with a greater difference observed in those with eGFR 45 to 60 mL/min/1.73 m<sup>2</sup> [<a href="#rid4">4</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Experimental and unproven measures for the prevention of ischemic ATN</span><span class="headingEndMark"> — </span>Multiple pharmacologic agents have been studied for the prevention of ischemic ATN. Selected measures are discussed here.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diuretics</strong> – As noted, we do not administer diuretics as prophylaxis for ischemic ATN [<a href="#rid40">40-42</a>]. This is consistent with the 2012 KDIGO guidelines [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">Although animal models of AKI have suggested that loop diuretics and <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> minimize kidney injury [<a href="#rid44">44-46</a>], this has not been shown in clinical studies. For example, no benefit and a possible detrimental effect of <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> were shown in a study in which 126 patients with normal kidney function were randomly assigned to a continuous infusion of furosemide, low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, or isotonic <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a>, all initiated at the beginning of elective cardiac surgery and continued for 48 hours [<a href="#rid40">40</a>]. </p><p></p><p class="bulletIndent1">Uncontrolled studies of patients with recent onset of oliguria and kidney function impairment (who may not yet have established AKI) have shown that patients who respond to <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">furosemide</a> and <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> or <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">mannitol</a> with an increase in urine output have a better outcome than nonresponders [<a href="#rid47">47-49</a>]. However, the responders may simply have had less severe disease, as evidenced by a shorter duration of oliguria (&lt;24 hours), a higher urine output, and a higher urine osmolality (suggesting better preservation of tubular function). Additionally, a multicenter, prospective, observational study including 17 Finnish intensive care units (ICUs) suggested that pre-ICU use of diuretics was an independent risk factor for development of AKI (OR 1.68, 95% CI 1.41-2.00) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dopamine</strong><strong>, </strong><strong>fenoldopam</strong><strong>, atrial natriuretic factor</strong> – We do not use <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>, or atrial natriuretic factor to prevent ischemic ATN. This is consistent with the 2012 KDIGO guidelines [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dopamine</strong> – Numerous placebo-controlled studies and meta-analyses have found that low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> is ineffective in preventing ATN [<a href="#rid40">40,51-55</a>].</p><p></p><p class="bulletIndent1">In addition, there is some evidence that low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> may cause harm by reducing renal blood flow in patients with early ischemic ATN, in contrast to the typical dopamine-induced increase in renal blood flow observed in normal subjects [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1">There are potential risks associated with low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, including tachycardia, arrhythmias (particularly among cardiac surgery patients), myocardial ischemia, and intestinal ischemia (due to precapillary vasoconstriction), which might promote bacterial translocation from the intestinal lumen into the systemic circulation [<a href="#rid48">48,56,57</a>]. In one study in cardiac surgery patients, for example, low-dose dopamine was independently associated with an increased risk of postoperative atrial fibrillation [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fenoldopam</strong> – Clinical equipoise exists for the use of the <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> receptor-1 agonist, <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>, to prevent ischemic AKI, and we believe further adequately powered randomized trials are warranted before it is used.</p><p></p><p class="bulletIndent1">Some studies have shown benefit, while others have not confirmed a clinically relevant benefit [<a href="#rid58">58-66</a>]. These trials have been limited in part due to small sample size and design. The most informative studies are discussed here:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a 2007 meta-analysis that included 16 randomized studies with a total of 622 patients administered <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a> and 668 given placebo or other therapy (principally low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>), fenoldopam reduced the risk for AKI (OR 0.43, 95% CI 0.32-0.59), need for KRT (OR 0.54, 95% CI 0.34-0.84), and in-hospital death (OR 0.65, 95% CI 0.45-0.91) [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent2">Limitations with this analysis included the lack of consistent criteria for initiating KRT, heterogeneity of enrolled patients (both surgical and nonsurgical critically ill patients), lack of placebo control in six studies, and inability to independently verify the change in glomerular filtration with infusion of <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>This meta-analysis was followed by the largest randomized trial in critically ill patients with AKI, which showed no difference in KRT, length of ICU stay, or mortality but showed increased incidence of hypotension in patients receiving <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a> [<a href="#rid67">67</a>]. This study was stopped early due to futility. The limitations of the study were ill-defined criteria for initiating KRT, and AKI was defined by the RIFLE classification, rather than more recent criteria.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a subsequent systematic review and meta-analysis that included six randomized, controlled trials of 507 surgical patients (undergoing cardiovascular surgery, partial nephrectomy, and liver transplant), <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a> reduced the risk of AKI (OR 0.46, 95% CI 0.27-0.79) [<a href="#rid68">68</a>]. However, there was no difference in the risks of KRT and hospital mortality [<a href="#rid68">68</a>]. Although there was little statistical evidence of heterogeneity among the randomized trials, there was heterogeneity in the definition of AKI, and results may not be extrapolated to other surgeries. In addition, most of the randomized trials were underpowered, and mortality data were available for 130 patients only.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atrial natriuretic peptides (ANP)</strong> – We do not use natriuretic peptides for prophylaxis against ATN, although some studies suggest benefit [<a href="#rid69">69-71</a>]. Natriuretic peptides block tubular reabsorption of sodium, vasodilate afferent arterioles, and inhibit the renin-angiotensin system.</p><p></p><p class="bulletIndent1">Among the best data is a meta-analysis that included 13 randomized trials and 934 adult patients with cardiovascular surgery-associated kidney dysfunction [<a href="#rid69">69</a>]. A subgroup analysis showed a reduction in dialysis-requiring AKI in patients receiving ANP compared with controls (OR 0.32, 95% CI 0.15-0.66). Interpretation of this meta-analysis is limited by the small size and variable quality of the included trials.</p><p></p><p class="bulletIndent1">A randomized trial that was published after the meta-analysis showed that, among 285 patients with CKD who were undergoing on-pump CABG, patients who received ANP had a smaller postoperative rise in serum creatinine compared with control (1.27 versus 1.46 mg/dL) [<a href="#rid72">72</a>]. In the early postoperative period, fewer patients in the ANP group required dialysis compared with control (one versus eight). At one year, only one patient from the ANP group was on dialysis versus five in the placebo group. At the time of publication, the study drug, carperitide, was only available in Japan, although the authors suggest that <a class="drug drug_general" data-topicid="10128" href="/z/d/drug information/10128.html" rel="external">nesiritide</a> may be equivalent [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasopressin</strong> – One randomized trial evaluated the early use of <a class="drug drug_general" data-topicid="10039" href="/z/d/drug information/10039.html" rel="external">vasopressin</a> to reduce the risk of kidney failure compared with <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">norepinephrine</a> in patients with septic shock. The results demonstrate that the early use of vasopressin compared with norepinephrine did not improve the number of kidney failure-free days and should not be used in place of norepinephrine [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Vasopressin and analogs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> – We agree with the 2012 KDIGO guidelines that recommend <strong>not</strong> administering N-acetylcysteine to patients to prevent ischemic ATN [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1">Several systematic reviews and meta-analyses have examined the efficacy of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> in the prevention of AKI following surgery [<a href="#rid74">74-76</a>]. A 2009 meta-analysis that included 10 studies and 1193 patients found that N-acetylcysteine, compared with placebo, did not prevent dialysis-requiring AKI (OR 1.04, 95% CI 0.45-2.37) or an increase in serum creatinine concentration greater than 25 percent (OR 0.84, 95% CI 0.64-1.11) [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1">Two randomized trials published after the meta-analysis showed no benefit of <a class="drug drug_general" data-topicid="9317" href="/z/d/drug information/9317.html" rel="external">N-acetylcysteine</a> compared with placebo in decreasing the risk of AKI in patients with new-onset hypotension [<a href="#rid77">77</a>] or undergoing off-pump coronary artery bypass surgery compared with placebo [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intensive insulin therapy</strong> – We do not use intensive insulin therapy to prevent ATN among critically ill patients.</p><p></p><p class="bulletIndent1">A number of studies have suggested that intensive insulin therapy may provide a renoprotective effect, although AKI was always a secondary outcome in these trials [<a href="#rid79">79-83</a>].</p><p></p><p class="bulletIndent1">A 2007 meta-analysis that was performed on five studies (only three randomized trials; the other two were nonconcurrent prospective cohort studies) evaluated the effect of insulin therapy on outcomes including AKI among critically ill patients [<a href="#rid84">84</a>]. Although not statistically significant, intensive insulin therapy (target glucose of 80 to 100 mg/dL [4.4 to 5.6 mmol/L]) lowered the risk for dialysis compared with conventional insulin therapy (target glucose of 180 to 200 mg/dL [10 to 11 mmol/L]; RR 0.65, 95% CI 0.40-1.05).</p><p></p><p class="bulletIndent1">However, the largest trial was published subsequent to the meta-analysis and showed no benefit of intensive insulin [<a href="#rid83">83</a>]. This was the multicenter Normoglycemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial, which randomly assigned 6104 medical and surgical patients to either intensive therapy (target blood glucose level of 81 to 108 mg/dL [4.5 to 6 mmol/L]) or conventional glucose control (target blood glucose of &lt;180 mg/dL [&lt;10 mmol/L]) [<a href="#rid83">83</a>]. There was no difference in the percentage of patients requiring KRT or in the duration of KRT. Other outcomes of this trial are discussed separately.</p><p></p><p class="bulletIndent1">Intensive insulin therapy is also associated with adverse effects. In a multicenter randomized, controlled trial of patients with severe sepsis, intensive insulin therapy was associated with serious adverse events such as hypoglycemia, and the trial was stopped early due to safety reasons [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">Other outcomes associated with intensive insulin therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remote ischemic preconditioning</strong> – We do not use remote ischemic preconditioning (RIPC) to prevent ischemic ATN. </p><p></p><p class="bulletIndent1">RIPC is a minimally invasive procedure by which the deliberate induction of transient, nonlethal ischemia of an organ protects against subsequent ischemic injury of another organ. (See  <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">"Prevention of contrast-associated acute kidney injury related to angiography", section on 'Remote ischemic preconditioning'</a> and  <a class="medical medical_review" href="/z/d/html/1489.html" rel="external">"Myocardial ischemic conditioning: Clinical implications", section on 'Remote ischemic preconditioning'</a>.)</p><p></p><p class="bulletIndent1">Numerous clinical trials and meta-analyses have examined the effects of RIPC with conflicting results [<a href="#rid86">86-95</a>]. In addition, the safety of repeated episodes of transient ischemia has not been conclusively demonstrated [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1">The best data are from a meta-analysis of 28 randomized clinical trials and 6851 patients [<a href="#rid97">97</a>]. RIPC had no effect on the reduction of serum creatinine on postoperative day 1 (14 studies, 1022 participants), day 2 (9 studies, 770 participants), and day 3 (6 studies, 417 participants) [<a href="#rid97">97</a>]. RIPC also had no effect on need for dialysis (13 studies, 2417 participants), length of hospital stay (8 studies, 920 participants), or all-cause mortality (24 studies, 4931 participants).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other experimental measures include the administration of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a>, statins, corticosteroids, erythropoietin, glutamate [<a href="#rid98">98</a>], and angiotensin II.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sodium bicarbonate</strong> – We do not give <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> to prevent ischemic ATN. Although an early trial suggested that sodium bicarbonate may prevent ischemic ATN [<a href="#rid99">99</a>], subsequent studies suggested no benefit and, potentially, harm:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A phase-IIb, multicenter, randomized trial showed no benefit of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> compared with sodium chloride on the incidence of AKI following cardiac bypass [<a href="#rid100">100</a>]. Notably, hypertonic infusions were used in this study rather than hypotonic or isotonic solutions, which were used in the first trial [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A larger randomized trial that used an identical protocol to that used in the first study cited above [<a href="#rid99">99</a>] demonstrated a <strong>higher</strong> rate of AKI in the <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> compared with sodium chloride group (47.7 versus 36.4 percent), although this difference was not statistically significant in the adjusted analysis [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Statins</strong> – We do not give statins to prevent ischemic ATN. Although observational studies have suggested that statins are associated with reduced risk of ischemic AKI [<a href="#rid102">102-104</a>], placebo-controlled trials have not confirmed this observation [<a href="#rid105">105,106</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Corticosteroids</strong> – We do not use corticosteroids to prevent ischemic ATN. The effect of perioperative high-dose <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> on postoperative AKI was studied in a multinational, placebo-controlled, randomized trial including 7286 high-risk patients who were undergoing cardiac surgery [<a href="#rid107">107</a>]. Methylprednisolone did not reduce AKI irrespective of CKD status [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythropoietin</strong> – We do not use erythropoietin to prevent ATN. A placebo-controlled trial that used biomarkers (gamma-glutamyl transpeptidase and alkaline phosphatase) to identify patients at risk for AKI showed no difference between erythropoietin and placebo in the change in the plasma creatinine over four to seven days [<a href="#rid108">108</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Angiotensin II</strong> – ATN due to sepsis is associated with low blood pressure and altered renal hemodynamics [<a href="#rid109">109</a>]. Angiotensin II can improve blood pressure in patients with vasodilatory shock when conventional vasopressors have failed [<a href="#rid110">110</a>]. In such patients with AKI who require dialysis, angiotensin II may also reduce the number of dialysis-dependent days, although these findings are preliminary [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adenosine analogues</strong> – We do not use <a class="drug drug_general" data-topicid="10281" href="/z/d/drug information/10281.html" rel="external">theophylline</a> for prevention of AKI. (See  <a class="medical medical_review" href="/z/d/html/111976.html" rel="external">"Neonatal acute kidney injury: Evaluation, management, and prognosis", section on 'Theophylline and perinatal asphyxia'</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H1062219813"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>The early management of patients with established ischemic ATN should include a determination of the likely etiology; assessment of volume status, systemic hemodynamics, electrolytes, and acid-base status; and dose adjustment or discontinuation of medications. The approach to medication management in acute kidney injury (AKI) is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults", section on 'Medications'</a>.)</p><p>Therapeutic measures include the maintenance of optimal hemodynamic status to ensure kidney perfusion and the avoidance of potential nephrotoxins to prevent further kidney injury.</p><p>All other measures are to support the patient until the kidney recovers. (See  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a>.)</p><p class="headingAnchor" id="H2343198075"><span class="h2">No role for diuretics</span><span class="headingEndMark"> — </span>We do not use diuretics to treat ATN, although diuretics may be used to manage volume status. This is consistent with the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [<a href="#rid43">43</a>].</p><p>Among patients with ATN, numerous studies, including randomized trials, have shown that diuretics augment urine output but do not have an effect on kidney function or patient survival [<a href="#rid112">112-118</a>].</p><p>The dissociation between the diuretic-induced increase in urine output and lack of effect on kidney function recovery probably reflects the ability of the diuretic to enhance the urine output in the few nephrons that are still functioning but inability to recruit previously nonfunctioning nephrons.</p><p>Diuretics may be given for a limited time for volume control but such use should not postpone the initiation of dialysis (if required) [<a href="#rid119">119</a>]. (See  <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose", section on 'Urgent indications'</a>.)</p><p>Dosing related to loop diuretics is available in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/2310.html" rel="external">"Loop diuretics: Dosing and major side effects"</a>.)</p><p class="headingAnchor" id="H3256619519"><span class="h2">Experimental measures for the treatment of established ATN</span><span class="headingEndMark"> — </span>There are conflicting data concerning the benefit of other pharmacologic agents in the treatment of patients with established ischemic ATN. Selected agents are discussed here.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dopamine</strong><strong>, </strong><strong>fenoldopam</strong><strong>, and atrial natriuretic peptide</strong> – We agree with the 2012 KDIGO guidelines that <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>, <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>, and atrial natriuretic peptide (ANP) not be used to treat established ATN, as there is no convincing evidence for a benefit [<a href="#rid43">43</a>]. These agents are discussed here.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dopamine</strong> – Despite an increase in natriuresis, low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> is ineffective in the treatment of established ATN. The best data are from a meta-analysis of 61 trials that randomly assigned 3359 patients with, or at risk for, ATN to low-dose dopamine (≤5 mcg/kg per minute) or to either placebo or no therapy [<a href="#rid51">51</a>]. Low-dose dopamine had no effect on mortality or need for kidney replacement therapy (KRT), although urine output increased by 24 percent.</p><p></p><p class="bulletIndent1">There are potential risks associated with low-dose <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>. These include tachycardia, arrhythmias (particularly among cardiac surgery patients), myocardial ischemia, and intestinal ischemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fenoldopam</strong> – <a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">Fenoldopam</a> does not appear to provide any benefit to patients with established ATN [<a href="#rid67">67,120</a>]. The best data are from a multicenter, randomized trial that compared fenoldopam with placebo in 667 patients admitted to an intensive care unit (ICU) with AKI following cardiac surgery [<a href="#rid67">67</a>]. AKI was defined as a greater than 50 percent increase in serum creatinine from baseline or oliguria for more than six hours [<a href="#rid67">67</a>]. Compared with placebo, there was no decrease in the need for KRT or in 30-day mortality in patients who received fenoldopam. Hypotension occurred more frequently in the fenoldopam group compared with placebo (26 versus 15 percent, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Atrial natriuretic peptide</strong> – ANP has been evaluated in several major trials with variable results [<a href="#rid121">121-123</a>]. In one large, multicenter, randomized trial, there was no overall difference in dialysis-free survival between ANP- and placebo-treated groups [<a href="#rid122">122</a>]. However, whereas patients who were nonoliguric appeared to do worse with anaritide (48 versus 59 percent dialysis-free survival with placebo), oliguric patients did better with anaritide (27 versus 8 percent dialysis-free survival with placebo). As in other studies, the outcome was worse in patients with oliguric versus nonoliguric ATN. (See  <a class="medical medical_review" href="/z/d/html/7215.html" rel="external">"Nonoliguric versus oliguric acute kidney injury"</a>.)</p><p></p><p class="bulletIndent1">Given the observation that oliguric patients may have had a better outcome than nonoliguric individuals when administered anaritide, a randomized, prospective trial was performed that evaluated anaritide in oliguric ATN [<a href="#rid123">123</a>]. Among 222 such patients, a 24-hour infusion of anaritide (200 ng/kg per minute) provided <strong>no</strong> benefit compared with placebo.</p><p></p><p class="bulletIndent1">Low-dose ANP may provide some benefit. The prolonged administration of low-dose ANP (50 ng/kg per minute) was suggested to provide benefit in a study of 61 patients with postoperative ATN [<a href="#rid124">124</a>]. ANP or placebo was continued until KRT was required or the serum creatinine concentration had decreased below the study inclusion value. Prior to, or at, day 21, ANP resulted in a decreased frequency of KRT (6 versus 14 patients, hazard ratio [HR] 0.28, 95% CI 0.10-0.73).</p><p></p><p class="bulletIndent2">Despite these positive results, the study was small and underpowered.</p><p></p><p class="bulletIndent1">Subgroup analysis of a meta-analysis and Cochrane review that included patients from eight trials who had established ATN following surgery suggested that low-dose ANP may reduce dialysis requirements [<a href="#rid70">70,71</a>]. However, study heterogeneity, design weaknesses, and small numbers limit any conclusions that can be drawn regarding the use of natriuretic peptide as a treatment of ATN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – A variety of other agents have been used to reduce the duration or severity of ATN, including thyroid hormone [<a href="#rid125">125</a>], alkaline phosphatase [<a href="#rid126">126-132</a>], and insulin growth factor (IGF) [<a href="#rid133">133</a>]. There is no convincing evidence for a benefit of these agents in the treatment of established ATN.</p><p></p><p class="headingAnchor" id="H2107995446"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute kidney injury due to acute tubular necrosis</strong> – Acute kidney injury (AKI) is defined by a rise in the serum creatinine concentration or a decline in urine output that develops within hours to days. AKI is commonly, though not always, caused by acute tubular necrosis (ATN), particularly among critically ill hospitalized patients. (See <a class="local">'Acute kidney injury versus acute tubular necrosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identification of high-risk patients</strong> – Patients are at high risk of ischemic ATN if they have predisposing comorbidities and have conditions or are undergoing procedures associated with ATN. (See <a class="local">'Identification of high-risk patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Predisposing comorbidities </strong>– Comorbidities that predispose to ischemic ATN include chronic kidney disease (CKD; either reduced estimated glomerular filtration rate [eGFR] or proteinuria with normal eGFR), severe atherosclerosis, diabetes mellitus, advanced malignancy, obesity and/or poor nutrition, and heart failure. (See <a class="local">'Identification of high-risk patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Conditions and procedures associated with ATN</strong> – Conditions and procedures that are commonly associated with ischemic ATN include major surgery (particularly cardiac surgery, abdominal aortic aneurysm surgery, surgery to correct obstructive jaundice, emergent surgery, or re-exploration surgery), sepsis, marked hypovolemia, severe pancreatitis, cardiogenic shock, and hemorrhagic shock. (See <a class="local">'Identification of high-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interventions to decrease risk</strong> – Patients who are at high risk for ischemic ATN should have interventions to prevent AKI. Interventions include optimizing volume status and avoiding or stopping nephrotoxins, if possible. We do not administer any pharmacologic agent (such as diuretics or <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a>/<a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">fenoldopam</a>) for the prevention of ischemic ATN. (See <a class="local">'Interventions to decrease risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of ATN</strong> – Early measures to treat established ischemic ATN include the maintenance of adequate hemodynamic status to ensure kidney perfusion and the avoidance of potential nephrotoxins to prevent further kidney injury. We do not use diuretics or any other pharmacologic agents to treat ATN, although diuretics may be used to manage volume status. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Experimental therapies</strong> – Multiple pharmacologic agents and methods are under evaluation to assist in the prevention and treatment/recovery of ATN. (See <a class="local">'Experimental and unproven measures for the prevention of ischemic ATN'</a> above and <a class="local">'Experimental measures for the treatment of established ATN'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314:97.</a></li><li><a class="nounderline abstract_t">Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol 2006; 1:19.</a></li><li><a class="nounderline abstract_t">Billings FT 4th, Pretorius M, Schildcrout JS, et al. Obesity and oxidative stress predict AKI after cardiac surgery. J Am Soc Nephrol 2012; 23:1221.</a></li><li><a class="nounderline abstract_t">Onorati F, Presta P, Fuiano G, et al. A randomized trial of pulsatile perfusion using an intra-aortic balloon pump versus nonpulsatile perfusion on short-term changes in kidney function during cardiopulmonary bypass during myocardial reperfusion. Am J Kidney Dis 2007; 50:229.</a></li><li><a class="nounderline abstract_t">Thakar CV, Arrigain S, Worley S, et al. A clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005; 16:162.</a></li><li><a class="nounderline abstract_t">Berns AS. Nephrotoxicity of contrast media. Kidney Int 1989; 36:730.</a></li><li><a class="nounderline abstract_t">James MT, Hemmelgarn BR, Wiebe N, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 2010; 376:2096.</a></li><li><a class="nounderline abstract_t">Girman CJ, Kou TD, Brodovicz K, et al. Risk of acute renal failure in patients with Type 2 diabetes mellitus. Diabet Med 2012; 29:614.</a></li><li><a class="nounderline abstract_t">Oezkur M, Wagner M, Weismann D, et al. Chronic hyperglycemia is associated with acute kidney injury in patients undergoing CABG surgery--a cohort study. BMC Cardiovasc Disord 2015; 15:41.</a></li><li><a class="nounderline abstract_t">Wilson FP, Shashaty M, Testani J, et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet 2015; 385:1966.</a></li><li><a class="nounderline abstract_t">Lachance P, Villeneuve PM, Rewa OG, et al. Association between e-alert implementation for detection of acute kidney injury and outcomes: a systematic review. Nephrol Dial Transplant 2017; 32:265.</a></li><li><a class="nounderline abstract_t">Kashani KB. Automated acute kidney injury alerts. Kidney Int 2018; 94:484.</a></li><li><a class="nounderline abstract_t">Li T, Wu B, Li L, et al. Automated Electronic Alert for the Care and Outcomes of Adults With Acute Kidney Injury: A Randomized Clinical Trial. JAMA Netw Open 2024; 7:e2351710.</a></li><li><a class="nounderline abstract_t">Biswas A, Parikh CR, Feldman HI, et al. Identification of Patients Expected to Benefit from Electronic Alerts for Acute Kidney Injury. Clin J Am Soc Nephrol 2018; 13:842.</a></li><li><a class="nounderline abstract_t">Jiang W, Teng J, Xu J, et al. Dynamic Predictive Scores for Cardiac Surgery-Associated Acute Kidney Injury. J Am Heart Assoc 2016; 5.</a></li><li><a class="nounderline abstract_t">Koyner JL, Carey KA, Edelson DP, Churpek MM. The Development of a Machine Learning Inpatient Acute Kidney Injury Prediction Model. Crit Care Med 2018; 46:1070.</a></li><li><a class="nounderline abstract_t">Chiofolo C, Chbat N, Ghosh E, et al. Automated Continuous Acute Kidney Injury Prediction and Surveillance: A Random Forest Model. Mayo Clin Proc 2019; 94:783.</a></li><li><a class="nounderline abstract_t">Meersch M, Schmidt C, Hoffmeier A, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med 2017; 43:1551.</a></li><li><a class="nounderline abstract_t">Göcze I, Jauch D, Götz M, et al. Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study. Ann Surg 2018; 267:1013.</a></li><li><a class="nounderline abstract_t">Goldstein SL. Nephrotoxicities. F1000Res 2017; 6:55.</a></li><li><a class="nounderline abstract_t">Brienza N, Giglio MT, Marucci M, Fiore T. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. Crit Care Med 2009; 37:2079.</a></li><li><a class="nounderline abstract_t">Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg 2007; 94:427.</a></li><li><a class="nounderline abstract_t">Ragaller MJ, Theilen H, Koch T. Volume replacement in critically ill patients with acute renal failure. J Am Soc Nephrol 2001; 12 Suppl 17:S33.</a></li><li><a class="nounderline abstract_t">Boldt J, Brenner T, Lehmann A, et al. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Med 2003; 29:763.</a></li><li><a class="nounderline abstract_t">Sinha Ray A, Haikal A, Hammoud KA, Yu AS. Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2016; 11:2132.</a></li><li><a class="nounderline abstract_t">Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy 2014; 34:670.</a></li><li><a class="nounderline abstract_t">Zhao M, Sun S, Huang Z, et al. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clin J Am Soc Nephrol 2020; 16:70.</a></li><li><a class="nounderline abstract_t">Zhuo M, Paik JM, Wexler DJ, et al. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes. Am J Kidney Dis 2022; 79:858.</a></li><li><a class="nounderline abstract_t">Chung MC, Hung PH, Hsiao PJ, et al. Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan. JAMA Netw Open 2023; 6:e230453.</a></li><li><a class="nounderline abstract_t">Stallwood MI, Grayson AD, Mills K, Scawn ND. Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass. Ann Thorac Surg 2004; 77:968.</a></li><li><a class="nounderline abstract_t">Chawla LS, Zhao Y, Lough FC, et al. Off-pump versus on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function. J Am Soc Nephrol 2012; 23:1389.</a></li><li><a class="nounderline abstract_t">Wijeysundera DN, Beattie WS, Djaiani G, et al. Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies. J Am Coll Cardiol 2005; 46:872.</a></li><li><a class="nounderline abstract_t">Straka Z, Widimsky P, Jirasek K, et al. Off-pump versus on-pump coronary surgery: final results from a prospective randomized study PRAGUE-4. Ann Thorac Surg 2004; 77:789.</a></li><li><a class="nounderline abstract_t">Tang AT, Knott J, Nanson J, et al. A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients. Eur J Cardiothorac Surg 2002; 22:118.</a></li><li><a class="nounderline abstract_t">Chukwuemeka A, Weisel A, Maganti M, et al. Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis. Ann Thorac Surg 2005; 80:2148.</a></li><li><a class="nounderline abstract_t">Seabra VF, Alobaidi S, Balk EM, et al. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials. Clin J Am Soc Nephrol 2010; 5:1734.</a></li><li><a class="nounderline abstract_t">Di Mauro M, Gagliardi M, Iacò AL, et al. Does off-pump coronary surgery reduce postoperative acute renal failure? The importance of preoperative renal function. Ann Thorac Surg 2007; 84:1496.</a></li><li><a class="nounderline abstract_t">Lamy A, Devereaux PJ, Prabhakaran D, et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med 2012; 366:1489.</a></li><li><a class="nounderline abstract_t">Garg AX, Devereaux PJ, Yusuf S, et al. Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. JAMA 2014; 311:2191.</a></li><li><a class="nounderline abstract_t">Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 2000; 11:97.</a></li><li><a class="nounderline abstract_t">Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006; 333:420.</a></li><li><a class="nounderline abstract_t">Mahesh B, Yim B, Robson D, et al. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial. Eur J Cardiothorac Surg 2008; 33:370.</a></li><li><a class="nounderline abstract_t">KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2:8.</a></li><li><a class="nounderline abstract_t">Hanley MJ, Davidson K. Prior mannitol and furosemide infusion in a model of ischemic acute renal failure. Am J Physiol 1981; 241:F556.</a></li><li><a class="nounderline abstract_t">Schrier RW, Arnold PE, Gordon JA, Burke TJ. Protection of mitochondrial function by mannitol in ischemic acute renal failure. Am J Physiol 1984; 247:F365.</a></li><li><a class="nounderline abstract_t">Escalante B, Erlij D, Falck JR, McGiff JC. Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle. Science 1991; 251:799.</a></li><li><a class="nounderline abstract_t">Luke RG, Briggs JD, Allison ME, Kennedy AC. Factors determining response to mannitol in acute renal failure. Am J Med Sci 1970; 259:168.</a></li><li><a class="nounderline abstract_t">Graziani G, Cantaluppi A, Casati S, et al. Dopamine and frusemide in oliguric acute renal failure. Nephron 1984; 37:39.</a></li><li><a class="nounderline abstract_t">Szerlip HM. Renal-dose dopamine: fact and fiction. Ann Intern Med 1991; 115:153.</a></li><li><a class="nounderline abstract_t">Nisula S, Kaukonen KM, Vaara ST, et al. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med 2013; 39:420.</a></li><li><a class="nounderline abstract_t">Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142:510.</a></li><li><a class="nounderline abstract_t">Marik PE, Iglesias J. Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators. Am J Med 1999; 107:387.</a></li><li><a class="nounderline abstract_t">Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356:2139.</a></li><li><a class="nounderline abstract_t">Lauschke A, Teichgräber UK, Frei U, Eckardt KU. 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69:1669.</a></li><li><a class="nounderline abstract_t">Baldwin L, Henderson A, Hickman P. Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery. Ann Intern Med 1994; 120:744.</a></li><li><a class="nounderline abstract_t">Argalious M, Motta P, Khandwala F, et al. "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery. Crit Care Med 2005; 33:1327.</a></li><li><a class="nounderline abstract_t">Hoffman TM, Bush DM, Wernovsky G, et al. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. Ann Thorac Surg 2002; 74:1607.</a></li><li><a class="nounderline abstract_t">Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66:486.</a></li><li><a class="nounderline abstract_t">Noiri E, Gailit J, Sheth D, et al. Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int 1994; 46:1050.</a></li><li><a class="nounderline abstract_t">Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. Ann Thorac Surg 2004; 78:1332.</a></li><li><a class="nounderline abstract_t">Bove T, Landoni G, Calabrò MG, et al. Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005; 111:3230.</a></li><li><a class="nounderline abstract_t">Brienza N, Malcangi V, Dalfino L, et al. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Crit Care Med 2006; 34:707.</a></li><li><a class="nounderline abstract_t">Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 2005; 33:2451.</a></li><li><a class="nounderline abstract_t">Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49:56.</a></li><li><a class="nounderline abstract_t">Roasio A, Lobreglio R, Santin A, et al. Fenoldopam reduces the incidence of renal replacement therapy after cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22:23.</a></li><li><a class="nounderline abstract_t">Zangrillo A, Biondi-Zoccai GG, Frati E, et al. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. J Cardiothorac Vasc Anesth 2012; 26:407.</a></li><li><a class="nounderline abstract_t">Bove T, Zangrillo A, Guarracino F, et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 2014; 312:2244.</a></li><li><a class="nounderline abstract_t">Gillies MA, Kakar V, Parker RJ, et al. Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis. Crit Care 2015; 19:449.</a></li><li><a class="nounderline abstract_t">Nigwekar SU, Hix JK. The role of natriuretic peptide administration in cardiovascular surgery-associated renal dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2009; 23:151.</a></li><li><a class="nounderline abstract_t">Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for preventing and treating acute kidney injury. Cochrane Database Syst Rev 2009; :CD006028.</a></li><li><a class="nounderline abstract_t">Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK. Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4:261.</a></li><li><a class="nounderline abstract_t">Sezai A, Hata M, Niino T, et al. Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol 2011; 58:897.</a></li><li><a class="nounderline abstract_t">Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316:509.</a></li><li><a class="nounderline abstract_t">Adabag AS, Ishani A, Bloomfield HE, et al. Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials. Eur Heart J 2009; 30:1910.</a></li><li><a class="nounderline abstract_t">Baker WL, Anglade MW, Baker EL, et al. Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis. Eur J Cardiothorac Surg 2009; 35:521.</a></li><li><a class="nounderline abstract_t">Ho KM, Morgan DJ. Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery. Am J Kidney Dis 2009; 53:33.</a></li><li><a class="nounderline abstract_t">Fraga CM, Tomasi CD, Damasio DC, et al. N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial. Crit Care 2016; 20:331.</a></li><li><a class="nounderline abstract_t">Song JW, Shim JK, Soh S, et al. Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass. Nephrology (Carlton) 2015; 20:96.</a></li><li><a class="nounderline abstract_t">van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359.</a></li><li><a class="nounderline abstract_t">Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449.</a></li><li><a class="nounderline abstract_t">Wang LC, Lei S, Wu YC, et al. [Intensive insulin therapy in critically ill patients]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006; 18:748.</a></li><li><a class="nounderline abstract_t">Schetz M, Vanhorebeek I, Wouters PJ, et al. Tight blood glucose control is renoprotective in critically ill patients. J Am Soc Nephrol 2008; 19:571.</a></li><li><a class="nounderline abstract_t">NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.</a></li><li><a class="nounderline abstract_t">Thomas G, Rojas MC, Epstein SK, et al. Insulin therapy and acute kidney injury in critically ill patients a systematic review. Nephrol Dial Transplant 2007; 22:2849.</a></li><li><a class="nounderline abstract_t">Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.</a></li><li><a class="nounderline abstract_t">Venugopal V, Laing CM, Ludman A, et al. Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis 2010; 56:1043.</a></li><li><a class="nounderline abstract_t">Zimmerman RF, Ezeanuna PU, Kane JC, et al. Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. Kidney Int 2011; 80:861.</a></li><li><a class="nounderline abstract_t">Ali ZA, Callaghan CJ, Lim E, et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007; 116:I98.</a></li><li><a class="nounderline abstract_t">Deftereos S, Giannopoulos G, Tzalamouras V, et al. Renoprotective effect of remote ischemic post-conditioning by intermittent balloon inflations in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2013; 61:1949.</a></li><li><a class="nounderline abstract_t">Choi YS, Shim JK, Kim JC, et al. Effect of remote ischemic preconditioning on renal dysfunction after complex valvular heart surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2011; 142:148.</a></li><li><a class="nounderline abstract_t">Hausenloy DJ, Candilio L, Evans R, et al. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med 2015; 373:1408.</a></li><li><a class="nounderline abstract_t">Meybohm P, Bein B, Brosteanu O, et al. A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery. N Engl J Med 2015; 373:1397.</a></li><li><a class="nounderline abstract_t">Yang Y, Lang XB, Zhang P, et al. Remote ischemic preconditioning for prevention of acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2014; 64:574.</a></li><li><a class="nounderline abstract_t">Hu J, Liu S, Jia P, et al. Protection of remote ischemic preconditioning against acute kidney injury: a systematic review and meta-analysis. Crit Care 2016; 20:111.</a></li><li><a class="nounderline abstract_t">Zhou C, Jeon Y, Meybohm P, et al. Renoprotection by remote ischemic conditioning during elective coronary revascularization: A systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2016; 222:295.</a></li><li><a class="nounderline abstract_t">Pan JS, Sheikh-Hamad D. Remote ischemic preconditioning for kidney protection. JAMA 2015; 313:2124.</a></li><li><a class="nounderline abstract_t">Menting TP, Wever KE, Ozdemir-van Brunschot DM, et al. Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury. Cochrane Database Syst Rev 2017; 3:CD010777.</a></li><li><a class="nounderline abstract_t">Holm J, Vanky F, Svedjeholm R. Association of Glutamate Infusion With Risk of Acute Kidney Injury After Coronary Artery Bypass Surgery: A Pooled Analysis of 2 Randomized Clinical Trials. JAMA Netw Open 2024; 7:e2351743.</a></li><li><a class="nounderline abstract_t">Haase M, Haase-Fielitz A, Bellomo R, et al. Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009; 37:39.</a></li><li><a class="nounderline abstract_t">McGuinness SP, Parke RL, Bellomo R, et al. Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial. Crit Care Med 2013; 41:1599.</a></li><li><a class="nounderline abstract_t">Haase M, Haase-Fielitz A, Plass M, et al. Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial. PLoS Med 2013; 10:e1001426.</a></li><li><a class="nounderline abstract_t">Molnar AO, Coca SG, Devereaux PJ, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011; 22:939.</a></li><li><a class="nounderline abstract_t">Brunelli SM, Waikar SS, Bateman BT, et al. Preoperative statin use and postoperative acute kidney injury. Am J Med 2012; 125:1195.</a></li><li><a class="nounderline abstract_t">Layton JB, Kshirsagar AV, Simpson RJ Jr, et al. Effect of statin use on acute kidney injury risk following coronary artery bypass grafting. Am J Cardiol 2013; 111:823.</a></li><li><a class="nounderline abstract_t">Billings FT 4th, Hendricks PA, Schildcrout JS, et al. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA 2016; 315:877.</a></li><li><a class="nounderline abstract_t">Prowle JR, Calzavacca P, Licari E, et al. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. Nephrology (Carlton) 2012; 17:215.</a></li><li><a class="nounderline abstract_t">Garg AX, Vincent J, Cuerden M, et al. Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial. BMJ Open 2014; 4:e004842.</a></li><li><a class="nounderline abstract_t">Endre ZH, Walker RJ, Pickering JW, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 2010; 77:1020.</a></li><li><a class="nounderline abstract_t">Schrier RW, Wang W. Acute renal failure and sepsis. N Engl J Med 2004; 351:159.</a></li><li><a class="nounderline abstract_t">Khanna A, English SW, Wang XS, et al. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 2017; 377:419.</a></li><li><a class="nounderline abstract_t">Tumlin JA, Murugan R, Deane AM, et al. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med 2018; 46:949.</a></li><li><a class="nounderline abstract_t">Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547.</a></li><li><a class="nounderline abstract_t">Cantarovich F, Rangoonwala B, Lorenz H, et al. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44:402.</a></li><li><a class="nounderline abstract_t">Brown CB, Ogg CS, Cameron JS. High dose frusemide in acute renal failure: a controlled trial. Clin Nephrol 1981; 15:90.</a></li><li><a class="nounderline abstract_t">van der Voort PH, Boerma EC, Koopmans M, et al. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. Crit Care Med 2009; 37:533.</a></li><li><a class="nounderline abstract_t">Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32:1669.</a></li><li><a class="nounderline abstract_t">Wu VC, Lai CF, Shiao CC, et al. Effect of diuretic use on 30-day postdialysis mortality in critically ill patients receiving acute dialysis. PLoS One 2012; 7:e30836.</a></li><li><a class="nounderline abstract_t">Grams ME, Estrella MM, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol 2011; 6:966.</a></li><li><a class="nounderline abstract_t">Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA 2002; 288:2599.</a></li><li><a class="nounderline abstract_t">Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 2005; 46:26.</a></li><li><a class="nounderline abstract_t">Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994; 45:1731.</a></li><li><a class="nounderline abstract_t">Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336:828.</a></li><li><a class="nounderline abstract_t">Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36:767.</a></li><li><a class="nounderline abstract_t">Swärd K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32:1310.</a></li><li><a class="nounderline abstract_t">Acker CG, Singh AR, Flick RP, et al. A trial of thyroxine in acute renal failure. Kidney Int 2000; 57:293.</a></li><li><a class="nounderline abstract_t">Pickkers P, Mehta RL, Murray PT, et al. Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial. JAMA 2018; 320:1998.</a></li><li><a class="nounderline abstract_t">Beumer C, Wulferink M, Raaben W, et al. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J Pharmacol Exp Ther 2003; 307:737.</a></li><li><a class="nounderline abstract_t">Bentala H, Verweij WR, Huizinga-Van der Vlag A, et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 2002; 18:561.</a></li><li><a class="nounderline abstract_t">Koyama I, Matsunaga T, Harada T, et al. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem 2002; 35:455.</a></li><li><a class="nounderline abstract_t">van Veen SQ, van Vliet AK, Wulferink M, et al. Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice. Infect Immun 2005; 73:4309.</a></li><li><a class="nounderline abstract_t">Su F, Brands R, Wang Z, et al. Beneficial effects of alkaline phosphatase in septic shock. Crit Care Med 2006; 34:2182.</a></li><li><a class="nounderline abstract_t">Heemskerk S, Masereeuw R, Moesker O, et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 2009; 37:417.</a></li><li><a class="nounderline abstract_t">Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999; 55:2423.</a></li></ol></div><div id="topicVersionRevision">Topic 7224 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510383" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hemodynamically mediated acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699187" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute kidney injury associated with cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626819" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Obesity and oxidative stress predict AKI after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660024" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A randomized trial of pulsatile perfusion using an intra-aortic balloon pump versus nonpulsatile perfusion on short-term changes in kidney function during cardiopulmonary bypass during myocardial reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15563569" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A clinical score to predict acute renal failure after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2681935" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nephrotoxicity of contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21094997" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017349" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of acute renal failure in patients with Type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964053" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Chronic hyperglycemia is associated with acute kidney injury in patients undergoing CABG surgery--a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25726515" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088774" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Association between e-alert implementation for detection of acute kidney injury and outcomes: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728257" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Automated acute kidney injury alerts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38241047" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Automated Electronic Alert for the Care and Outcomes of Adults With Acute Kidney Injury: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29599299" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of Patients Expected to Benefit from Electronic Alerts for Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27491837" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dynamic Predictive Scores for Cardiac Surgery-Associated Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29596073" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Development of a Machine Learning Inpatient Acute Kidney Injury Prediction Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31054606" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Automated Continuous Acute Kidney Injury Prediction and Surveillance: A Random Forest Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110412" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28857811" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Biomarker-guided Intervention to Prevent Acute Kidney Injury After Major Surgery: The Prospective Randomized BigpAK Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28163909" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nephrotoxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384211" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17380548" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251029" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Volume replacement in critically ill patients with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665995" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27895134" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vancomycin and the Risk of AKI: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855041" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33376101" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34762974" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36811856" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14992908" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acute renal failure in coronary artery bypass surgery: independent effect of cardiopulmonary bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595302" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Off-pump versus on-pump coronary artery bypass grafting outcomes stratified by preoperative renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139139" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Off-pump coronary artery surgery for reducing mortality and morbidity: meta-analysis of randomized and observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14992872" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Off-pump versus on-pump coronary surgery: final results from a prospective randomized study PRAGUE-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12103384" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A prospective randomized study to evaluate the renoprotective action of beating heart coronary surgery in low risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305860" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Renal dysfunction in high-risk patients after on-pump and off-pump coronary artery bypass surgery: a propensity score analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20671222" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954051" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Does off-pump coronary surgery reduce postoperative acute renal failure? The importance of preoperative renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22449296" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Off-pump or on-pump coronary-artery bypass grafting at 30 days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24886787" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616845" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lack of renoprotective effects of dopamine and furosemide during cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16861256" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Meta-analysis of frusemide to prevent or treat acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18243724" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : KDIGO Clinical Practice Guideline for Acute Kidney Injury</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6795934" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prior mannitol and furosemide infusion in a model of ischemic acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6431829" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Protection of mitochondrial function by mannitol in ischemic acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846705" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of cytochrome P450 arachidonate metabolites on ion transport in rabbit kidney loop of Henle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5460470" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Factors determining response to mannitol in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6717704" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dopamine and frusemide in oliguric acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2058863" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Renal-dose dopamine: fact and fiction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23291734" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809463" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10527041" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Low-dose dopamine does not prevent acute renal failure in patients with septic shock and oliguria. NORASEPT II Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11191541" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572117" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8147547" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Effect of postoperative low-dose dopamine on renal function after elective major vascular surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942351" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : "Renal dose" dopamine is associated with the risk of new-onset atrial fibrillation after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12440616" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253694" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Inflammatory cells in ischemic acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7861698" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cyclic RGD peptides ameliorate ischemic acute renal failure in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15464494" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967861" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: a prospective, double-blind, randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505657" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16276165" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17185146" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249326" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Fenoldopam reduces the incidence of renal replacement therapy after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459931" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25265449" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26703329" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19167908" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The role of natriuretic peptide administration in cardiovascular surgery-associated renal dysfunction: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19821351" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Atrial natriuretic peptide for preventing and treating acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073785" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21851876" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose HANP Infusion Therapy during cardiac surgery) trial for CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27483065" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19282300" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a systematic review of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19147369" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18649982" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27745551" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : N-acetylcysteine plus deferoxamine for patients with prolonged hypotension does not decrease acute kidney injury incidence: a double blind, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25384603" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794168" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Intensive insulin therapy in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452557" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Intensive insulin therapy in the medical ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166358" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : [Intensive insulin therapy in critically ill patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18235100" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Tight blood glucose control is renoprotective in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318384" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Intensive versus conventional glucose control in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17604310" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Insulin therapy and acute kidney injury in critically ill patients a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184958" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Intensive insulin therapy and pentastarch resuscitation in severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974511" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21677633" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846333" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23500314" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Renoprotective effect of remote ischemic post-conditioning by intermittent balloon inflations in patients undergoing percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21272897" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effect of remote ischemic preconditioning on renal dysfunction after complex valvular heart surgery: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436207" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26436208" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24954246" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Remote ischemic preconditioning for prevention of acute kidney injury: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27095379" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Protection of remote ischemic preconditioning against acute kidney injury: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27498373" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Renoprotection by remote ischemic conditioning during elective coronary revascularization: A systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26024384" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Remote ischemic preconditioning for kidney protection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28258686" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38252440" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Association of Glutamate Infusion With Risk of Acute Kidney Injury After Coronary Artery Bypass Surgery: A Pooled Analysis of 2 Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19112278" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685640" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23610561" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493769" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Statin use associates with a lower incidence of acute kidney injury after major elective surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062398" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Preoperative statin use and postoperative acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23273532" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Effect of statin use on acute kidney injury risk following coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26906014" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22117606" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24598306" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164823" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247356" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Acute renal failure and sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528561" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Angiotensin II for the Treatment of Vasodilatory Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509568" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444861" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Diuretics, mortality, and nonrecovery of renal function in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15332212" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7011622" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : High dose frusemide in acute renal failure: a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114909" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286542" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Diuretics and mortality in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22431960" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of diuretic use on 30-day postdialysis mortality in critically ill patients receiving acute dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393482" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Fluid balance, diuretic use, and mortality in acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444868" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Loop diuretics for patients with acute renal failure: helpful or harmful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983954" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933821" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effects of atrial natriuretic peptide in clinical acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9062091" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007679" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187512" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620211" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A trial of thyroxine in acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30357272" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970380" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12462566" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12413606" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972524" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775571" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Beneficial effects of alkaline phosphatase in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19114895" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354291" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
